This is not deconditioning. This is not depression. You are profoundly ill. The research agrees with you.

Pacing isn't a cure — it's harm reduction. The defining feature of ME/CFS is post-exertional malaise (PEM): symptoms worsening 12–48 hours after physical, cognitive, or emotional exertion, sometimes for days or weeks. Every PEM crash appears to set patients back, and severe or repeated crashes are associated with disease progression. Pacing aims to keep you below your individual threshold so you stop crashing. Evidence level: Strong for harm reduction; the strongest patient outcome data we have.

In practice, pacing means heart rate monitoring (often using an anaerobic threshold around 55–60% of max heart rate, or 0.6 × (220 − age) as a starting estimate), aggressive scheduled rest (rest before tired, not after), breaking activities into very small blocks, and treating cognitive load (screens, conversations, decisions) as real exertion. Apps like Visible and Bearable are designed for this. Most patients who pace strictly for 6–12 months report a more stable baseline — not recovery, but room for other interventions to work.

For decades, graded exercise therapy (GET) was a guideline-recommended treatment based on the PACE trial — a study that has since been heavily critiqued for unblinded outcomes, post-hoc endpoint changes, and overlapping diagnostic criteria with depression. Patient surveys consistently show GET makes a substantial percentage of ME/CFS patients worse, sometimes permanently. The UK's NICE guideline removed GET as a treatment in 2021. The CDC removed it from its recommendations in 2017. Evidence level for harm: Strong, from large patient cohorts.

That doesn't mean all movement is dangerous. Many patients can do gentle, recumbent activity (stretching, lying-down yoga, very short walks) without triggering PEM, especially if heart rate stays below the anaerobic threshold. The principle is: never push, always stop before symptoms worsen, and never increase intensity on a fixed schedule. Movement is something you fit inside the energy envelope, not something you grow it with. Anyone — physical therapist, doctor, family member — pushing you to exercise more aggressively is working from outdated guidance.

Low-dose naltrexone (LDN) is one of the few medications with reasonable evidence and a favorable safety profile in ME/CFS. Mechanism is thought to involve glial cell modulation and reduced neuroinflammation. Multiple case series and a couple of small open-label studies show partial benefit in fatigue, pain, and cognitive symptoms in roughly half to two-thirds of patients who try it. Evidence level: Emerging, but the best we have for a disease-modifying medication candidate.

Typical protocol is starting at 0.5 or 1.5 mg and titrating up to 3–4.5 mg over weeks. Side effects, when they occur, are usually vivid dreams or short-term sleep changes that often resolve. Compounding pharmacies prepare it; the standard 50 mg naltrexone tablet is too high. Most general practitioners won't prescribe it because it's off-label, but ME/CFS-literate doctors, pain specialists, and functional medicine physicians often will. It's worth asking about. It's also worth knowing that LDN is not a quick win — give it 3–6 months at a stable dose before deciding if it helps.

POTS — postural orthostatic tachycardia syndrome — is one of the most common comorbidities in ME/CFS, present in an estimated 25–50% of patients. Symptoms overlap heavily: lightheadedness on standing, brain fog, racing heart, fatigue worse upright. The treatments differ enough that having both diagnosed matters. A simple 10-minute active stand test (heart rate lying down, then at 1, 3, 5, and 10 minutes standing) can suggest POTS — a sustained increase of 30+ bpm in adults, 40+ bpm in adolescents, without a significant blood pressure drop, is the threshold.

First-line POTS treatment is non-pharmaceutical: salt loading (often 8–10 g/day with medical guidance), 2–3 L of fluid, compression garments to mid-abdomen if tolerated, and recumbent reconditioning. Medications used include pyridostigmine (Mestinon) — which has a small but interesting evidence base in ME/CFS even outside POTS, possibly via neuromuscular and autonomic mechanisms — ivabradine, beta blockers, midodrine, and fludrocortisone. Pyridostigmine in particular is worth knowing about: some ME/CFS specialists trial it for fatigue and orthostatic symptoms, and many patients report meaningful improvement.

The honest answer: no supplement has strong evidence in ME/CFS. Several have weak-to-moderate evidence and are reasonable to consider with a doctor: CoQ10 (small studies show modest fatigue improvement, often combined with NADH), D-ribose (mixed data, popular in the ME/CFS community), magnesium glycinate (better-evidenced for sleep and pain in adjacent conditions), and basic deficiency correction — vitamin D, B12 (methylcobalamin or hydroxocobalamin if MTHFR variants), iron/ferritin if low, omega-3.

Be much more skeptical of: expensive mitochondrial "protocols," IV nutrient drips, peptide stacks (BPC-157, thymosin), proprietary blends marketed for chronic fatigue, methylation panels driving multi-supplement regimens, and anything making cure claims. NAD+ infusions and NAD+ precursors (NMN, NR) are popular but human evidence in ME/CFS is essentially absent. If you're going to try a supplement, try one at a time, allow 6–8 weeks, and track symptoms carefully — small benefits matter and can be missed if you're stacking ten things at once.

Three diagnostic frameworks are widely used. The Canadian Consensus Criteria (CCC, 2003) and the International Consensus Criteria (ICC, 2011) are stricter — they require post-exertional malaise as mandatory along with multi-system features. The 2015 Institute of Medicine criteria (now NAM) are simpler: substantial reduction in function for 6+ months, post-exertional malaise, unrefreshing sleep, plus either cognitive impairment or orthostatic intolerance. Most US clinicians who diagnose ME/CFS use the IOM/NAM criteria; researchers often prefer CCC.

There is no diagnostic blood test. Diagnosis is clinical and is partly a process of ruling out mimics: hypothyroidism (with full panel including free T3, free T4, TPO antibodies), B12 and iron deficiencies, sleep apnea, autoimmune disease, primary cardiac causes, and depression with somatic features (which ME/CFS is not, but they can coexist). If you suspect ME/CFS and your doctor isn't familiar, the Bateman Horne Center, the US ME/CFS Clinician Coalition, and Mayo Clinic guidelines have published clinician resources you can bring to your appointment. Diagnosis matters — it changes treatment, disability documentation, and the questions you ask going forward.